Additionally, LSC47 and KMT2A fusion partner risk both remain significant when we consider our entire cohort, suggesting that integrating the LSC47 gene signature and KMT2A fusion partner risk groups further augments the prognostic modeling for patients with KMT2A fusion positive AML and additional studies are underway. This evidence concerns the gene KMT2A and acute myeloid leukemia.